TYRA Dabogratinib: 57% CR, First Oral Bladder Cancer Drug

Tyra Biosciences (TYRA) reported initial Phase 2 SURF302 results for oral dabogratinib, a selective FGFR3 inhibitor, in low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The 60 mg once-daily dose produced a 79% overall response rate (11/14) and a 57% three-month complete response rate in the combined population, missing the company’s stated ~70% CR bar. Shares dropped roughly 20% to $22.01 on about 6 million shares, roughly 10 times normal volume.

The single-marker-lesion subgroup told a different story. In the eight patients whose minimal residual disease best mirrors the planned adjuvant setting, dabogratinib at 60 mg hit a 100% overall response rate (8/8) and a 75% best-overall-response CR rate. The 50 mg dose, tested in 12 patients, showed 67% ORR and 33% CR. Tyra is advancing the 60 mg dose into a registrational adjuvant Phase 3.

Dabogratinib is the only investigational oral FGFR3-selective therapy in clinical development for this indication. FGFR3 mutations drive roughly 70% of low-grade NMIBC cases. The drug emerged from Tyra’s in-house SNÅP platform and selectively targets FGFR3 while sparing FGFR1, FGFR2, and FGFR4, a selectivity profile designed to avoid the hyperphosphatemia and off-target toxicities that have limited earlier pan-FGFR inhibitors. Existing treatments require repeated catheterization and office-based procedures that many patients consider worse than surveillance. A once-daily oral option could change treatment for the roughly 760,000 Americans living with bladder cancer.

Safety was clean: no Grade 3 treatment-related adverse events at 60 mg, no hyperphosphatemia, no nail or ocular toxicity, and no Grade 4 or 5 events. This matters because FGFR inhibitors historically carry hyperphosphatemia and ocular toxicity baggage that dabogratinib appears to avoid at the therapeutic dose. The profile supports chronic once-daily dosing.

Tyra is also advancing dabogratinib in two other trials: SURF303 in low-grade upper tract urothelial cancer, where the first treated patient achieved a complete response at the three-month assessment with no adverse events, and BEACH301 in pediatric achondroplasia, which has cleared five dose levels without safety signals.

The 57% headline CR missed the bar, and at n=14 the data is thin. But the single-lesion cohort data justify a Phase 3, and the clean safety profile removes a major class-wide risk. The planned adjuvant trial will need to confirm durable responses in a larger population with longer follow-up.

For a guide to interpreting early-stage oncology readouts, see how to read a clinical trial press release. Tyra ended Q2 2026 with roughly $450 million in cash, sufficient to fund operations through the planned Phase 3 readout.

Source: Tyra SURF302 press release · ClinicalTrials.gov: SURF302

What It Means for the Trade

The 20% drop to $22.01 on 10x volume is the market reading the headline — 57% CR versus a ~70% bar — and nothing else. That is a defensible first reaction but an incomplete analysis. The combined population mixes two very different clinical situations, and the subgroup that actually mirrors the planned Phase 3 adjuvant setting — single-marker-lesion minimal residual disease — posted 100% ORR (8/8) and 75% best-response CR at 60 mg. If you believe the adjuvant population is the registrational population, the subgroup number, not the pooled miss, is the one that predicts Phase 3. Tyra advancing the 60 mg dose into a registrational Phase 3 says the company read it that way too — though it is the company’s own trial design being validated by its own subgroup.

The honest caveat is sample size. Fourteen pooled patients, eight in the subgroup, n=1 in the upper-tract trial: these are directions, not distributions. A 100% ORR at n=8 has a confidence interval that includes very ordinary results. The stock’s reaction priced the miss; the Phase 3 initiation will re-price the story, and the gap between now and that readout is measured in years.

Mechanism and Market Context

The selectivity design is the actual asset here. FGFR3 mutations drive roughly 70% of low-grade NMIBC, but earlier FGFR inhibitors — the erdafitinib class — hit FGFR1-4 broadly, producing hyperphosphatemia, ocular toxicity, and nail toxicity that limit chronic dosing. Dabogratinib spares FGFR1/2/4 while hitting FGFR3, and the SURF302 safety data show exactly what that design was built to deliver: no Grade 3 treatment-related events at 60 mg, no hyperphosphatemia, no ocular or nail toxicity. For a drug meant to be taken chronically in a surveillance-setting cancer population, that clean profile is arguably worth more than a single CR-rate datapoint.

The treatment-context gap is real and underserved. Low-risk NMIBC patients today choose between repeated catheterization with intravesical therapy and office procedures, or surveillance — and many pick surveillance, accepting recurrence risk to avoid the procedures. An oral once-daily pill shifts that calculus, in a bladder-cancer population of roughly 760,000 Americans. The adjuvant setting Tyra is targeting — post-resection patients with residual risk — is where an oral agent has the clearest value proposition.

Risks and What Could Go Wrong

1. Phase 3 conversion. Phase 2 to Phase 3 CR-rate disappointments are the most common failure pattern in NMIBC; the 57% pooled number is a warning about mixed-population enrollment, and even the adjuvant design depends on durable responses in larger numbers.
2. Small-n noise. Every subgroup statistic in this readout rests on single-digit patient counts.
3. Competing standards. Surveillance is free; an oral drug must beat do-nothing economics, and payers will demand recurrence-reduction data, not just response rates. This is a platform-quality asset in a small biotech — position sized for the Phase 3 initiation news, not for the subgroup to hold up.